Company intelligence / Profile preview

BoomRay Pharmaceuticals Co., Ltd.

Ownership: Private
Development stage: Phase 1

Overview

Currently conducting Phase I clinical trial of PET tracer [18F]BF3-BPA injection for diagnosis of primary and metastatic brain tumors; first subject enrollment completed in April 2024

Therapeutic areas: Oncology
Modalities: Radionuclide Drug Conjugates (RDC)Radioactive Targeted Drugs (RTD)Small Molecular Radionuclide Conjugates (SMRC)
Industry: Biotech

Drug pipeline

10 assets

[18F]BF3-BPA

9 more assets in the full pipeline.

Partnerships

Peking UniversityZhongshan Hospital (Fudan University)WuXi AppTec

Beyond the preview

Go deeper on BoomRay Pharmaceuticals Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BoomRay Pharmaceuticals Co., Ltd..